The pancreatic-protocol CT scan — what it shows, and what it decides

Most people reach this page after typing something close to “ct scan pancreatic cancer” into a search box, usually within a day or two of being handed a request form or a report they do not fully understand. The first thing worth knowing is that the scan being asked for is not an ordinary abdominal CT. It has its own recipe, and the recipe is the point.

You will see it called several things — pancreatic protocol CT, contrast CT pancreas, multiphase or triple-phase CT of the abdomen. They all describe the same study. Contrast is injected into a vein, and the scanner then takes more than one pass through the abdomen at carefully chosen moments as that contrast travels: once before it arrives, once while it is still filling the arteries and lighting up the pancreas itself, and once later when it has reached the veins and the liver. The pancreas is scanned in thin slices throughout, so the images can be rebuilt afterwards in any plane the radiologist needs.

The timing is the whole trick. A pancreatic tumour and normal pancreatic tissue take up contrast at different speeds, so on a single-pass scan they can look almost the same and a tumour can be missed or badly underestimated. On a properly timed study the gland brightens, a tumour tends to stay darker against it, and the arteries and veins sitting immediately behind the pancreas are separately and clearly outlined. That last part matters more than anything else on the scan, because those vessels decide what is surgically possible.

So a pancreatic-protocol CT is asked to answer three questions at once: is there a mass in the pancreas, how does it sit against the blood vessels behind it, and is there any sign of disease elsewhere — particularly in the liver or on the lining of the abdomen. Everything that follows on this page is about those three questions. For the wider picture — symptoms, staging, treatment and what comes after — start from our complete guide to pancreatic cancer. This page stays with the scan.

1. 1

   A blood test first, in most cases

   Kidney function is usually checked before intravenous contrast is given, and liver enzymes are often taken at the same time because they say something about the bile ducts. What each of those results means is set out in blood and liver function tests in pancreatic cancer.

   In-house at CION
2. 2

   Fasting, and a cannula in the arm

   You will usually be asked not to eat for a few hours beforehand. A small cannula goes into a vein in the arm or hand for the contrast, and you may be given plain water to drink shortly before, which helps separate the stomach and duodenum from the pancreas on the images.

   In-house at CION
3. 3

   The passes through the scanner

   You lie on your back and the table moves through the ring. There is a first pass without contrast, then the contrast is injected and further passes are taken at set moments as it moves through the arteries and then the veins. You will be asked to hold your breath briefly each time. The scanning itself takes minutes, not hours.

   In-house at CION
4. 4

   The warm flush, which surprises people

   As the contrast goes in, most people feel a spreading warmth and a brief metallic taste, and often a strong sensation of having passed urine when they have not. All of that is expected and passes in moments. Tell the team beforehand about any previous contrast reaction, asthma, kidney disease, or diabetes medication.

   In-house at CION
5. 5

   Reporting by a radiologist

   The report is not written in the room. A radiologist works through the thin slices and the reconstructions, describing where any mass sits, what the pancreatic and bile ducts are doing, exactly how the tumour meets each nearby artery and vein, and whether there is anything suspicious in the liver or elsewhere.

   In-house at CION
6. 6

   Review as a team, not by one person

   The images then go to a multidisciplinary discussion — medical and radiation oncology at CION, with hepatobiliary surgical and endoscopy colleagues at partner centres — because resectability is a group judgement made on the pictures themselves, not on the wording of a report.

   Coordinated with specialist partner centres

• Where the mass is, and how big. Head, neck, body or tail. Position matters more than most people expect: a tumour in the head blocks the bile duct early and announces itself with jaundice, while one in the tail can grow quietly for far longer.
• What the ducts are doing. A dilated bile duct and a dilated pancreatic duct together — often written as the “double duct sign” — is a pattern that always prompts a careful look at the head of the pancreas.
• How the tumour meets each vessel. The report will name the arteries and veins individually and describe abutment, contact or encasement. This is the single most consequential paragraph in the whole document, and it is explained properly in vascular involvement in pancreatic cancer.
• A resectability category, or the words to build one. Resectable, borderline resectable, locally advanced or metastatic. That category, far more than the size in millimetres, is what determines whether the first conversation is about surgery or about systemic treatment first.
• The liver, the peritoneum and the nodes. Scanned deliberately, because this is where pancreatic cancer most often spreads. Deposits too small to see on any scan are exactly why a staging laparoscopy is sometimes added before a planned operation.
• Hedged language, which is normal. “Indeterminate”, “cannot be excluded” and “suggest correlation” are a radiologist being honest about the limits of a picture, not a hidden verdict. They usually mean another test is needed, most often an MRI with MRCP or an endoscopic ultrasound.
• “No focal lesion identified” is not always the end of it. Some tumours take up contrast almost identically to the surrounding gland and are genuinely hard to see. If symptoms persist, that finding is a reason to look again with a different test, not a reason to stop looking.

1. 1

   A free 45-minute consultation, with the images open

   The first appointment is long enough to look at the actual images with you, not only the typed report. Bring the discs or the link as well as the printout — a report describes what a radiologist saw, and the pictures are what a treating team plans from.

   In-house at CION
2. 2

   The scan itself, arranged and reported here

   Where a pancreatic-protocol study is needed, it is ordered, performed and reported through CION, with the wider role of the test explained on our CT scan in cancer diagnosis and staging page. MRI with MRCP, CA 19-9 and bloods are ordered and reported the same way.

   In-house at CION
3. 3

   An honest answer on whether it needs repeating

   Many outside scans are perfectly adequate and get used as they are. Some were done as a general abdominal study, without the timed phases, and cannot answer the vessel question. We will tell you which of those you have, and why, rather than quietly reordering.

   In-house at CION
4. 4

   Tissue, where tissue is needed

   If a sample is required, endoscopic ultrasound with FNA is arranged with specialist endoscopy partners and may be billed there. How the different routes compare is set out in how a pancreatic biopsy is done.

   Coordinated with specialist partner centres
5. 5

   A plan, once the scan and the tissue agree

   Chemotherapy, radiation, chemoradiation and SBRT, nutrition and enzyme support, pain and psycho-oncology care are delivered by CION across 35+ centres. Any pancreatic operation, along with endoscopic stenting and staging laparoscopy, is coordinated with partner centres. The full pathway is set out in pancreatic cancer treatment in Hyderabad.

   In-house planning, coordinated surgery

A CT shows shape, density and behaviour. It does not show cells. A mass in the head of the pancreas with a dilated duct behind it and a blocked bile duct is a picture that most specialists would find highly suggestive — and it is still a picture. Several other things produce the same appearance: a mass formed by long-standing chronic inflammation, autoimmune pancreatitis, an unusual lymphoma, a deposit from a cancer that started elsewhere, or a neuroendocrine tumour, which tends to brighten sharply on the arterial phase rather than staying dark and carries a completely different outlook and treatment plan.

That is why a tissue sample is usually taken before non-surgical treatment begins, and why the pathology report matters as much as the scan does. What that document contains, and how to read the parts that are actually about you, is set out in understanding your pancreatic cancer pathology report. The pathologist also grades the tumour — a description of how closely the cells still resemble normal pancreatic tissue — and that is explained in pancreatic cancer grade and differentiation.

There is one important exception worth stating, because it confuses people. Where the imaging is classic and surgery is planned straight away, a biopsy beforehand is sometimes deliberately skipped, and the diagnosis is confirmed on the tissue removed at the operation instead. Not being sent for a biopsy is therefore not a sign of neglect. It usually means the team has judged that the sample would not change the next step.

The reverse holds too. A scan that looks worrying is not a verdict, and people are told so far too rarely. Until a pathologist has looked down a microscope, or a team has followed the appearance over time and watched it behave, what you have is a strong impression from a very good picture — and a specialist will say exactly that if you ask.

Even a well-performed pancreatic-protocol CT has real blind spots, and knowing them is more useful than assuming the scan settles everything. Very small tumours, particularly in the tail, can sit below what the scan can resolve. Some tumours take up contrast at almost the same rate as the gland around them and are close to invisible against it, betraying themselves only by a subtle change in the contour of the pancreas or by an unexplained duct cut-off. Tiny deposits scattered on the peritoneum are below the resolution of any current scanner, which is the entire reason staging laparoscopy exists.

This is also why nobody should read a pancreatic-protocol CT as a general reassurance test. It is ordered because of a symptom, an abnormal blood result or an incidental finding, and it is interpreted against that specific question. A scan reported as normal answers the question that was asked on the day it was done; if a symptom persists or changes, the right response is to go back, not to point at the old report.

The harder question — whether pancreatic cancer can be caught before it causes symptoms at all — is answered honestly on can pancreatic cancer be found early?. In short: there is no population screening programme for pancreatic cancer anywhere, because the disease is uncommon enough that scanning healthy people would generate far more false alarms, unnecessary procedures and anxiety than it would prevent harm. Structured surveillance imaging is offered only to a small group at genuinely high inherited risk, and it is arranged through a specialist service rather than requested casually.

What that leaves is the practical version, and it is worth saying without decoration. Painless yellowing of the eyes or skin should be checked the same week, whatever else is going on. Persistent upper abdominal or back pain, unexplained weight loss, or diabetes appearing for the first time in later life are worth a proper assessment rather than a wait-and-see. And a scan already done deserves to be explained to you by someone who will sit with the images.

Medical disclaimer: This page explains what a pancreatic-protocol CT scan involves and what its report describes, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma. It is general information and not an interpretation of your own scan; your images and report must be read alongside your history, examination and other tests by a doctor who knows your case. Ordering, arranging and reporting of pancreatic-protocol CT and of MRI with MRCP, CA 19-9 and routine bloods, multidisciplinary treatment planning, chemotherapy, radiation, chemoradiation and SBRT, genetic counselling, nutrition and pancreatic enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION. Endoscopic ultrasound and EUS-FNA biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, peptide receptor radionuclide therapy, and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.